| | |
n(%)
|
P-Value
|
|---|
|
Positive (n = 28)
|
Negative (n = 95)
|
|---|
|
Age Group
|
≤70 years
|
16(57.1)
|
61(64.2)
|
0.497
|
|
> 70 years
|
12(42.9)
|
34(35.8)
|
|
Total gleason score
|
6
|
4(14.3)
|
35(36.8)
|
0.029
|
|
7
|
5(17.9)
|
24(25.3)
|
|
8
|
8(28.6)
|
19(20)
|
|
9
|
11(39.3)
|
17(17.9)
|
|
WHO grade groupª
|
Grade 1
|
4(14.3)
|
35(36.8)
|
0.014
|
|
Grade 2
|
3(10.7)
|
22(23.2)
|
|
Grade 3
|
2(7.1)
|
2(2.1)
|
|
Grade 4
|
8(28.6)
|
19(20)
|
|
Grade 5
|
11(39.3)
|
17(17.9)
|
|
Tumor Quantification
|
< 10%
|
3(10.7)
|
20(21.1)
|
0.028
|
|
10–50%
|
4(14.3)
|
31(32.6)
|
|
> 50%
|
21(75)
|
44(46.3)
|
|
Perineural invasion
|
Present
|
14(50)
|
32(33.7)
|
0.117
|
|
Absent
|
14(50)
|
63(66.3)
|
|
Lymphovascular invasionª
|
Present
|
0(0)
|
3(3.2)
|
1.000
|
|
Absent
|
28(100)
|
92(96.8)
|
|
Extraprostatic extensionª
|
Present
|
0(0)
|
7(7.4)
|
0.349
|
|
Absent
|
28(100)
|
88(92.6)
|
|
Seminal vesicle invasion ª
|
Present
|
2(7.1)
|
2(2.1)
|
0.222
|
|
Absent
|
26(92.9)
|
93(97.9)
|
|
Recurrence
|
Yes
|
19(67.9)
|
14(14.7)
|
< 0.001
|
|
No
|
9(32.1)
|
81(85.3)
|
|
EGFR
|
Positive
|
8(28.6)
|
92(96.8)
|
< 0.001
|
|
Negative
|
20(71.4)
|
3(3.2)
|
- Chi square test was applied
- ªFisher exact test applied
- P-Value≤0.05, considered as significant
